Literature DB >> 16444581

Inhibition of adenosine kinase by phosphonate and bisphosphonate derivatives.

Jae Park1, Bhag Singh, Radhey S Gupta.   

Abstract

The enzyme adenosine kinase (AK) plays a central role in regulating the intracellular and interstitial concentration of the purine nucleoside adenosine (Ado). In view of the beneficial effects of Ado in protecting tissues from ischemia and other stresses, there is much interest in developing AK inhibitors, which can regulate Ado concentration in a site- and event-specific manner. The catalytic activity of AK from different sources is dependent upon the presence of activators such as phosphate (Pi). In this work we describe several new phosphorylated compounds which either activate or inhibit AK. The compounds acetyl phosphate, carbamoyl phosphate, dihydroxyacetone phosphate and imidodiphosphate were found to stimulate AK activity in a dose-dependent manner comparable to that seen with Pi. In contrast, a number of phosphonate and bisphosphonate derivatives, which included clodronate and etidronate, were found to inhibit the activity of purified AK in the presence of Pi. These AK inhibitors (viz. clodronate, etidronate, phosphonoacetic acid, 2-carboxyethylphosphonic acid, N-(phosphonomethyl)-glycine and N-(phosphonomethyl)iminodiacetic acid), at concentrations at which they inhibited AK, were also shown to inhibit the uptake of (3)H-adenosine and its incorporation into macromolecules in cultured mammalian cells, indicating that they were also inhibiting AK in intact cells. The drug concentrations at which these effects were observed showed limited toxicity to the cultured cells, indicating that these effects are not caused by cellular toxicity. These results indicate that the enzyme AK provides an additional cellular target for the clinically widely used bisphosphonates and related compounds, which could possibly be exploited for a new therapeutic application. Our structure-activity studies on different AK activators and inhibitors also indicate that all of the AK activating compounds have a higher partial positive charge (delta(+)) on the central phosphorous atom in comparison to the inhibitors. This information should prove helpful in the design and synthesis of more potent inhibitors of AK.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16444581     DOI: 10.1007/s11010-006-2216-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  49 in total

1.  Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy.

Authors:  J B Wiesner; B G Ugarkar; A J Castellino; J Barankiewicz; D P Dumas; H E Gruber; A C Foster; M D Erion
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

2.  Pentavalent ions dependency is a conserved property of adenosine kinase from diverse sources: identification of a novel motif implicated in phosphate and magnesium ion binding and substrate inhibition.

Authors:  Mary C Maj; Bhag Singh; Radhey S Gupta
Journal:  Biochemistry       Date:  2002-03-26       Impact factor: 3.162

3.  Crystal structures of Toxoplasma gondii adenosine kinase reveal a novel catalytic mechanism and prodrug binding.

Authors:  M A Schumacher; D M Scott; I I Mathews; S E Ealick; D S Roos; B Ullman; R G Brennan
Journal:  J Mol Biol       Date:  2000-05-19       Impact factor: 5.469

4.  Some properties of partially purified mammalian adenosine kinase.

Authors:  B Lindberg; H Klenow; K Hansen
Journal:  J Biol Chem       Date:  1967-02-10       Impact factor: 5.157

Review 5.  The role of adenosine in the regulation of coronary blood flow.

Authors:  R M Berne
Journal:  Circ Res       Date:  1980-12       Impact factor: 17.367

Review 6.  Adenosine, oxidative stress and cytoprotection.

Authors:  V Ramkumar; D M Hallam; Z Nie
Journal:  Jpn J Pharmacol       Date:  2001-07

7.  Studies on several pyrrolo[2,3-d]pyrimidine analogues of adenosine which lack significant agonist activity at A1 and A2 receptors but have potent pharmacological activity in vivo.

Authors:  L P Davies; J Baird-Lambert; J F Marwood
Journal:  Biochem Pharmacol       Date:  1986-09-15       Impact factor: 5.858

8.  Spinal cord adenosine receptor stimulation in rats inhibits peripheral neutrophil accumulation. The role of N-methyl-D-aspartate receptors.

Authors:  G W Bong; S Rosengren; G S Firestein
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

9.  Adenosine inhibits ischemia-reperfusion-induced leukocyte adherence and extravasation.

Authors:  M B Grisham; L A Hernandez; D N Granger
Journal:  Am J Physiol       Date:  1989-11

10.  Structure of human adenosine kinase at 1.5 A resolution.

Authors:  I I Mathews; M D Erion; S E Ealick
Journal:  Biochemistry       Date:  1998-11-10       Impact factor: 3.162

View more
  3 in total

Review 1.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

2.  Identification and biochemical studies on novel non-nucleoside inhibitors of the enzyme adenosine kinase.

Authors:  Jae Park; Gayathri Vaidyanathan; Bhag Singh; Radhey S Gupta
Journal:  Protein J       Date:  2007-04       Impact factor: 4.000

Review 3.  Phosphonate and Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthases: A Structure-Guided Perspective.

Authors:  Jaeok Park; Vishal R Pandya; Sean J Ezekiel; Albert M Berghuis
Journal:  Front Chem       Date:  2021-01-06       Impact factor: 5.221

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.